I did not know Astella owns a piece of Xtandi.  

When I read this NR it didn't make sense to me initially... i thought why are they doing another phase 2 trial with a new partner for the same prostate cancer condition?

A few searches later... the last trial with Pfizer for mCRPC was a 1b/2a trial.  This trial with Astella is phase 2b.  Looks like the normal continuation or progression of steps forward.

Fun fact - Astella is based in Tokyo with ~16,000 employees.  $29 Billion USD market cap.  Looks to have an active Oncology program.

from wiki

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. On February 5, 2020, the company announced management changes effective from April 1, 2020. Astellas is a member of the Mitsubishi UFJ Financial Group keiretsu.